An official website of the United States government
Home
Name
R-CVP
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for R-CVP
Name
Alternate Names
Anti-CD20 monoclonal antibodies
C2B8 monoclonal antibody
IDEC-C2B8
MabThera
Monoclonal antibody IDEC-C2B8
Rituxan
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic monoclonal antibody
NSC Number
687451
Primary Site
Leukemia
NHL
Histology
None
Remarks
December 2, 2021 The FDA approved rituximab (Rituxan, Genentech, Inc.) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.
FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.
FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.
FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.
FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.
June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
.
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.
FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.
FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.
FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.
FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.
June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
.
Coding
This drug should be coded
Name
Alternate Names
Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719
Abbreviations
CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
026271
26271
Primary Site
Breast
leukemia
lymphoma
multiple myeloma
neuroblastoma
ovarian cancer
retinoblastoma
soft tissue sarcoma
Wilm's tumor
Histology
None
Remarks
An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent
Coding
This drug should be coded
Name
Alternate Names
component of Ataraxoid
Component of K Predne-Dome#
Cortalone
Delta-Cortef
Fernisolon
Fernisolone-P
Hydeltra
Meti-Derm
Minims Prednisolone
Novo-Prednisolone
Paracortol#
Pre-Pred
Predne-Dome#
Prednicen
Prelone
Ster 5
Sterane
Vitacort
Abbreviations
PRDL
Category
Hormones and hormonal mechanisms
Subcategory
Glucocorticoid
NSC Number
009120
9120
Primary Site
None
Histology
None
Remarks
A synthetic corticosteroid (glucocorticoid) and an analogue of cortisol. Administered orally in replacement therapy for adrenocortical insufficiency and as an anti-inflammatory in a wide variety of conditions.
Coding
This drug should be coded
Name
Alternate Names
Compound 37231
Leurocristine Sulfate
Oncovin
Vincasar
Vincasar PFS
Vincristine Sulfate
Vincrystine
Vinkristin
Abbreviations
LCR
VCR
VNCR
Category
Chemotherapy
Subcategory
Plant alkyloid--antimetabolite
NSC Number
067574
67574
Primary Site
None
Histology
None
Remarks
Antineoplastic; vinca plant alkaloid; antimetabolite. FDA approved uses in ALL, Hodgkin's lymphoma, non-Hodgkin's lymphoma, neuroblastoma, rhabomyosarcoma, and Wilm's tumor.
Coding
This drug should be coded
